STOK

26.7700.59%
AO

Arthur O. Tzianabos

Chairman of the Board

Dr. Arthur O. Tzianabos, Ph.D., is Chairman of the Board of Stoke Therapeutics, Inc. from October 6, 2025 and has been its Director since September 2018 and served as its Interim Executive Chairman from March 19, 2025 to October 6, 2025 and was its Independent Director since September 2018 and was its Chairman since September 2024. He serves as the President, Chief Executive Officer and Director of Lifordi Immunotherapeutics Inc. Dr. Arthur serves as Director of Q32 Bio Inc. since March 25, 2024. Dr. Tzianabos previously served as the Chairman of Board since September 2022 to March 2024 and has served as a member of Board since April 2016. Dr. Arthu has of experience in the biotechnology industry and academia leading teams in the discovery, development, clinical translation and commercialization of new treatments for immunology and rare diseases. He is Venture Partner of 5AM Venture Management, LLC from September 2022. Dr. Tzianabos joined the 5AM Venture Management, LLC in 2022. He serves as the Chairman of the Board of Homology Medicines, Inc. since September 2022. He had been the Chief Executive Officer of Homology Medicines, Inc. since April 2016 until September 2022 and serves as its Director since April 2016 and was President since April 2016 until September 2022. He joined Homology Medicines, Inc. in 2016. He serves on the Board of Oxford Biomedica Solutions. Dr. Tzianabos serves as a Director of Alliance for Regenerative Medicine. He served as the President and Chief Scientific Officer of OvaScience, Inc. from September 2013 to March 31, 2016. He served as a Vice President of Program Management, Head of Research and Early Development and Senior Vice President at Shire plc. He has extensive experience in drug discovery and development, strategic planning, portfolio management, business development and alliance management. During his tenure at Shire, he served in roles of increasing responsibility and was instrumental in the development of the human genetic therapies pipeline following Shire's acquisition of Transkaryotic Therapies, Inc. in 2005. Dr. Tzianabos joined Shire in 2005 as Senior Director, Discovery Research and was instrumental in establishing the Discovery Research group and played a leading role in the expansion of Shire HGT research pipeline shortly after the acquisition of TKT by Shire. He serves as Chair of Scientific Advisory Board at OvaScience, Inc. He has been a Member of Scientific Advisory Board at Agilis Biotherapeutics, LLC since June 2014 and as its Director since September 2015. He served as Director of ArmaGen Technologies, Inc. since December 2012. He served as a Director of bluebird bio. From 1992 to 2005, Dr. Tzianabos was a faculty Member at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women's Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. His research at Harvard led to the discovery of a new class of immunoregulatory, T cell-dependent antigens, which formed the basis for technologies licensed by two biotechnology companies and Eli Lilly and Company for clinical development. During his time at Harvard, he served as a Consultant to several biotechnology companies, including Genzyme Corporation and Eli Lilly. He served as the Chairman of the Board at Akouos, Inc. since August 2020 until December 1, 2022. He had been a Director of Akouos, Inc. since July 2018 until December 1, 2022. He had been a Director of BIND Therapeutics, Inc. since October 2015 to July 2016. Dr. Tzianabos serves as a Venture Partner at 5AM Ventures, where he has focused on life sciences investments since September 2022. He served as a Director of DNIB Unwind, Inc. since October 2015. Dr. Tzianabos has published more than 80 scientific papers, book chapters and patents in the field of immunology, glycobiology and infectious disease. He holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire. Dr. Tzianabos serves on the Development Board of the College of Life Sciences and Agriculture at the University of New Hampshire.

Positions